Subscription Required

Only paid subscribers* to Drug Benefit News can access this Web portal with three years of back issues, searchable article archives and other valuable resources.

Subscribers to Drug Benefit News receive

  • 24 biweekly issues (8 pages) of timely news and insightful strategies for reducing costs and improving outcomes, delivered First Class by U.S. Mail and electronically
  • Special E-Alerts when timely news breaks
  • Access to your subscriber-only web page with:
    • A posting of the latest issue
    • Searchable archives of all articles for the past three years
    • A chronological posting of back issues for three years
  • Recent stories of interest and hot topic articles grouped for convenient reading and regular postings from your editor
View a sample and get more information
November 21, 2014

Recent Stories of Interest

From Drug Benefit News - As payers anticipate the final wave of patent expirations and generic launches in the U.S., their expectations were somewhat deflated this month when Ranbaxy Laboratories Ltd. disclosed that the FDA revoked its tentative approval to market generic Nexium (esomeprazole magnesium) as early as this year. But in an interesting turn of events, Ranbaxy is now suing the federal agency that rescinded its provisional approvals to launch that drug and a generic version of Roche Holding’s antiviral drug Valcyte (valganciclovir hydrochloride). Read more

The “generic wave” peaked in 2012 when roughly $32 billion worth of… Read more

During recent conference calls to discuss third-quarter 2014 earnings, the three large… Read more

After issuing draft guidance in September for Medicare Part D sponsors on… Read more

From the Editor

Welcome to your Drug Benefit News subscriber-only Web page

Be sure to visit often, for PDFs of issues, archives of articles and data, and more!

Please e-mail me with comments on the last issue of Drug Benefit News, story ideas for future issues or any other suggestions you have that can make the newsletter more useful for you.

November 21, 2014
Senate Introduces Legislation to Address Generic Price Increases in Medicaid

Sen. Sanders unveils a bill requiring generic drugmakers to pay Medicaid extra rebates if prices outpace inflation.

November 20, 2014
Global Drug Spend Will Rise 30% by 2018

IMS Health report predicts 30% increase in global spending on medicines by 2018, to $1.3 trillion. Specialty drugs will contribute 40% of the growth, and almost 200 new drugs are expected to launch in the next five years.

November 18, 2014
Ranbaxy Sues FDA for Revoking Generic Approvals

Ranbaxy sues FDA for rescinding tentative approvals to launch generic versions of Nexium, Valcyte:

Updated Regularly

Featured Hot Topics

Search for your own Hot Topics

It's quick and easy to sign up for FREE access to!

Why do I need to register?